Leadership in health care private equity since 1986

The Latest News

May 20, 2019

UCB announces NAYZILAM® (midazolam) nasal spray now approved by FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy in the U.S.>

  • NAYZILAM® (midazolam) nasal spray* is a nasally administered benzodiazepine indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 12 years of age and older.    
  • NAYZILAM allows for administration by a non-healthcare professional in patients actively seizing when and where a seizure cluster occurs.
  • Approval of NAYZILAM adds to UCB’s already existing anti-epilepsy drug portfolio, reinforcing the company’s position as a global leader in epilepsy.
April 24, 2019

Exagen's New Biomarker Available to Offer Insight into Thrombosis for Lupus Sufferers>

Lupus Patients with Elevated PC4d Levels Have Significantly Increased Occurrence of Thrombosis

April 15, 2019

Alphatec Announces Sales Leadership Appointment And Successful Closing Of Expanded Credit Facility With Squadron Capital>

Experienced Spine Executive David Sponsel Assumes Sales Leadership Role

March 28, 2019

Alphatec Announces Commercial Launch Of Its First IdentiTi™ Porous Titanium Interbody System>

IdentiTi implants are 60% porous, which enhances intra-operative and post-operative imaging.


March 27, 2019

ElectroCore Announces Fourth Quarter and Full Year 2018 Financial Results>

Fourth quarter 2018 prescription growth of more than 30% from third quarter 2018

March 26, 2019

Jeffrey Thomas Elliott, CFA Joins Exagen’s Board of Directors>

Jeff Elliott adds relevant experience to Exagen’s Board of Directors as a former diagnostics analyst at Robert W. Baird & Co. and as the current CFO of Exact Sciences
March 14, 2019

ElectroCore Announces Encouraging Research Supporting Key Areas of Clinical Development for its Non-Invasive Vagus Nerve Stimulator, gammaCore™>

Data presented at the 3rd International Brain Stimulation Conference support the use of nVNS for treatment of mild traumatic brain injury and rheumatoid arthritis

March 08, 2019

ElectroCore Appoints Multiple Industry Veterans to Key Management Positions>

Dr. Tony Fiorino to serve as Chief Medical Officer and Brian Posner as Chief Financial Officer

February 26, 2019

Exagen and the Lupus Foundation of America Partner on New Initiative to Reduce the Time to an Accurate Lupus Diagnosis>

New tools and resources will be shared in English and Spanish through physican offices, websites and social media. 

February 26, 2019

ElectroCore Announces Positive Coverage Policies of gammaCore Issued by Highmark>

gammaCore may be medically necessary for the abortive treatment of episodic migraine and episodic cluster headaches

February 25, 2019

Alphatec Announces FDA Clearance Of Its Automated SafeOp Neuromonitoring System>

Addresses Significant Unmet Needs In Spine Surgery

February 19, 2019

ElectroCore and HealthyWomen Announce Partnership>

Patient Program to Increase Awareness of Non-Drug Migraine Therapies

January 08, 2019

ElectroCore Announces Two New Studies and a Publication>

Findings Support the Practical Utility of Non-invasive Vagus Nerve Stimulation in Adults

January 08, 2019

ElectroCore Announces Two New Studies and a Publication>

Increasing Support of the Practical Utility of Non-invasive Vagus Nerve Stimulation in Adults

January 02, 2019

Exagen Enters Second-Year Agreement with GSK>

Collaboration to drive greater awareness about challenges facing lupus diagnosis and management 

January 02, 2019

GammaCore™ Now Available Through U.S. Federal Government’s Federal Supply Schedule (FSS)>

Five-year contract makes gammaCore™ available to the over 21 million patients managed within the Department of Veteran’s Affairs, Department of DefenseBureau of PrisonsIndian Health Servicesand Public Health Services

November 28, 2018

ElectroCore Receives FDA Clearance for gammaCore™ (nVNS) for Adjunctive Use for the Preventive Treatment of Cluster Headache in Adults>

First and only product FDA cleared for the prevention of cluster headache. There are currently no FDA-approved pharmacologic treatments for the prevention of cluster headache.

November 27, 2018

ElectroCore Expands Manufacturing Capabilities for gammaCore™>

New design and development facility to support increasing patient demand.

November 13, 2018

ElectroCore, Inc. Announces Third Quarter Financial Results>

Fnancial results for the three months and nine months ended September 30, 2018.

November 08, 2018

Alphatec Reports Third Quarter 2018 Financial and Corporate Highlights>

Results for the third quarter ended September 30, 2018 and corporate highlights.